Effects of oral administration of rotenone on gastrointestinal functions in mice

Neurogastroenterology and Motility

Volumn 25, Issue 3, 2013, Pages

  Tasselli, M ^a,b,c   Chaumette, T ^a,b,c   Paillusson, S ^a,b,c   Monnet, Y ^a,d,e   Lafoux, A ^a,b   Huchet Cadiou, C ^a,b   Aubert, P ^a,b,c   Hunot, S ^a,d,e   Derkinderen, P ^a,b,c   Neunlist, M ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d CNRS   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Alpha synuclein; Enteric nervous system; Epithelial intestinal barrier; Gastrointestinal dysfunction; Parkinson's disease; Rotenone

Indexed keywords

ALPHA SYNUCLEIN; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EX VIVO STUDY; FECES ANALYSIS; FOOD INTAKE; GANGLION; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT FUNCTION; IMMUNOREACTIVITY; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; INTESTINE TRANSIT TIME; JEJUNUM; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH EMPTYING; SUBSTANTIA NIGRA PARS COMPACTA;

ADMINISTRATION, ORAL; ANIMALS; GASTROINTESTINAL MOTILITY; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MYENTERIC PLEXUS; NEURONS; ROTENONE; SUBSTANTIA NIGRA; UNCOUPLING AGENTS;

EID: 84874020427     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12070     Document Type: Article

References (33)

1. Sherer TB, Richardson JR, Testa CM et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 2007; 100: 1469-79.
2. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-6.
3. Inden M, Kitamura Y, Takeuchi H et al. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007; 101: 1491-504.
4. Tanner CM, Kamel F, Ross GW et al. Rotenone, paraquat and Parkinson's disease. Environ Health Perspect 2011; 119: 866-72.
5. Beach TG, Adler CH, Sue LI et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2009; 119: 689-702.
6. Schemann M, Neunlist M. The human enteric nervous system. Neurogastroenterol Motil 2004; 16(Suppl 1): 55-9.
7. Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De Giorgio R. Parkinson disease: the enteric nervous system spills its guts. Neurology 2011; 77: 1761-7.
8. Lebouvier T, Chaumette T, Paillusson S et al. The second brain and Parkinson's disease. Eur J Neurosci 2009; 30: 735-41.
9. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006; 396: 67-72.
10. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 2009; 36: 96-102.
11. Greene JG, Noorian AR, Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp Neurol 2009; 218: 154-61.
12. Pan-Montojo F, Anichtchik O, Dening Y et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 2010; 5: e8762.
13. Brochard V, Combadiere B, Prigent A et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119: 182-92.
14. Abeliovich A, Schmitz Y, Farinas I et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25: 239-52.
15. Nagakura Y, Naitoh Y, Kamato T, Yamano M, Miyata K. Compounds possessing 5-HT3 receptor antagonistic activity inhibit intestinal propulsion in mice. Eur J Pharmacol 1996; 311: 67-72.
16. Baudry C, Reichardt F, Marchix J, Schemann M, Bruley des Varannes S, Moriez R. Diet-induced obesity has neuroprotective effects in murine gastric enteric nervous system: involvement of leptin and glial cell line-derived neurotrophic factor. J Physiol 2012; 590: 533-44.
17. Osinski MA, Bass P, Gaumnitz EA. Peripheral and central actions of orphanin FQ (nociceptin) on murine colon. Am J Physiol 1999; 276: G125-31.
18. De Quelen F, Chevalier J, Rolli-Derkinderen M, Mourot J, Neunlist M, Boudry G. n-3 polyunsaturated fatty acids in the maternal diet modify the postnatal development of nervous regulation of intestinal permeability in piglets. J Physiol 2011; 589: 4341-52.
19. Aube AC, Cabarrocas J, Bauer J et al. Changes in enteric neurone phenotype and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut 2006; 55: 630-7.
20. Blandini F, Baklestra B, Levandis G et al. Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. Neurosci Lett 2009; 467: 203-7.
21. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism & Related Disorders 2011; 17: 10-5.
22. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson's disease: a pilot study. Mov Disord 2006; 21: 1270-3.
23. Savidge TC, Sofroniew MV, Neunlist M. Starring roles for astroglia in barrier pathologies of gut and brain. Lab Invest 2007; 87: 731-6.
24. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 362-81.
25. Neunlist M, Van Landeghem L, Bourreille A, Savidge T. Neuro-glial crosstalk in inflammatory bowel disease. J Intern Med 2008; 263: 577-83.
26. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33: 599-614.
27. Salat-Foix D, Tran K, Ranawaya R, Meddings J, Suchowersky O. Increased intestinal permeability and Parkinson disease patients: chicken or egg?. Can J Neurol Sci 2012; 39: 185-8.
28. Forsyth CB, Shannon KM, Kordower JH et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS ONE 2011; 6: e28032.
29. Anderson G, Noorian AR, Taylor G et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp Neurol 2007; 207: 4-12.
30. Natale G, Kastsiushenka O, Fulceri F, Ruggieri S, Paparelli A, Fornai F. MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut. Brain Res 2010; 1355: 195-206.
31. Tian YM, Chen X, Luo DZ et al. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. Neuroscience 2008; 153: 634-44.
32. Chaumette T, Lebouvier T, Aubert P et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol Motil 2009; 21: 215-22.
33. Hoglinger GU, Oertel WH, Hirsch EC. The rotenone model of parkinsonism - the five years inspection. J Neural Transm Suppl 2006; 70: 269-72.